ClinicalTrials.gg
CompletedNCT02954354CAPSTONE 1Updated May 8, 2019Results posted

A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza

A Phase 3 interventional study of Baloxavir Marboxil and Placebo to Baloxavir Marboxil in Influenza, sponsored by Shionogi. Completed. Open to participants aged 12 Years to 64 Years. Per ClinicalTrials.gov, last updated 2019-05-08.

Sponsored by Shionogi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,436
Allocation
Randomized
Ages
12 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing baloxavir in Influenza, Human — 7 open to participants now, 7 under way, 5 of them phase 3. baloxavir · Influenza, Human.

Enrollment
5th of 18
1,436 · median 483
Started
2016
with 1 other
Phase 3
12 of 18
5 open now
Registered
2nd of 18
by date
Lead sponsor
2 of 18
Shionogi

Among the 18 studies testing baloxavir in Influenza, Human, this one is the 5th largest by enrollment, is one of 2 that started in 2016, is one of 12 in phase 3, and was the 2nd registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

7 of the 18 studies testing baloxavir in Influenza, Human are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About baloxavir

baloxavir: first FDA approval 2018 (XOFLUZA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 12 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baloxavir in Influenza, Human, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to alleviation of symptoms in patients with uncomplicated influenza virus infection.

03

Conditions studied

  • Influenza

Browse trials for

Keywords

  • Flu
  • Baloxavir Marboxil
  • Oseltamivir
  • Tamiflu®
04

Who can participate

Ages eligible
12 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who are able to understand the study and comply with all study procedures, and willing to provide written /assent prior to the predose examinations appropriately. As for adolescent patients, informed consent/assent of voluntary participation should be obtained in accordance with local requirements
  2. Male or female patients aged ≥ 12 to ≤ 64 years at the time of signing the informed consent/assent form.
  3. Patients with a diagnosis of influenza virus infection confirmed by all of the following:

    1. Fever ≥ 38ºC (axillary) in the predose examinations or > 4 hours after dosing of antipyretics if they were taken
    2. At least one of the following general systemic symptoms associated with influenza are present with a severity of moderate or greater

      • Headache
      • Feverishness or chills
      • Muscle or joint pain
      • Fatigue
    3. At least one of the following respiratory symptoms associated with influenza are present with a severity of moderate or greater

      • Cough
      • Sore throat
      • Nasal congestion
  4. The time interval between the onset of symptoms and the predose examinations is 48 hours or less. The onset of symptoms is defined as either:

    1. Time of the first increase in body temperature (an increase of at least 1ºC from normal body temperature)
    2. Time when the patient experiences at least one general or respiratory symptom
  5. Women of who agree to use a highly effective method of for 3 months after the first dose of study drug

Exclusion criteria

Exclusion Criteria:

  1. Patients with severe influenza virus infection requiring inpatient treatment.
  2. Patients aged ≥ 20 years with known allergy to oseltamivir (Tamiflu®).
  3. Patients with any of the following risk factors

    1. Women who are pregnant or within 2 weeks post-partum
    2. Residents of long-term care facilities (eg, welfare facilities for the elderly, nursing homes)
    3. Chronic respiratory diseases including bronchial asthma
    4. Neurological and neurodevelopmental disorders including disorders of the brain, spinal cord, peripheral nerve, and muscle (eg, cerebral palsy, epilepsy [seizure disorders], stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury)
    5. Heart disease (such as congenital heart disease, congestive heart failure, or coronary artery disease), excluding hypertension without any other heart-related symptoms)
    6. American Indians and Alaskan natives
    7. Blood disorders (such as sickle cell disease)
    8. Endocrine disorders (including diabetes mellitus)
    9. Kidney disorders
    10. Liver disorders
    11. Metabolic disorders
    12. Compromised immune system (including patients receiving therapy, or those with cancer or [HIV] infection)
    13. Morbid obesity ( [BMI] ≥ 40)
  4. Patients unable to swallow tablets or capsules.
  5. Patients who have previously received Baloxavir Marboxil.
  6. Patients weighing \< 40 kg
  7. Patients who have been exposed to an drug within 30 days prior to the predose examinations.
  8. Women who are breastfeeding or have a positive pregnancy test in the predose examinations. The following female patients who have documentation of either a or b below do not need to undergo a pregnancy test in the predose examinations:

    1. (defined as cessation of regular menstrual periods for 2 years or more and confirmed by a follicle-stimulating hormone test) women
    2. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or tubal ligation
  9. Patients with concurrent infections requiring systemic antimicrobial and/or antiviral therapy at the predose examinations.
  10. Patients who have received peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir, or amantadine within 30 days prior to the predose examinations.
  11. Patients who have received an investigational monoclonal antibody for a viral disease in the last year.
  12. Patients with severe underlying diseases.
  13. Patients with known ≤ 60 mL/min.
  14. Patients who, in the opinion of the investigator, would be unlikely to comply with required study visits, self-assessments, and interventions
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,436 participants (actual)

Study arms

  • Experimental
    Adults: Baloxavir Marboxil

    Participants aged 20 to 64 years will receive two or four 20 mg baloxavir marboxil tablets orally on Day 1 and one oseltamivir placebo capsule orally twice a day (BID) on Days 1 to 5.

    Drug: Baloxavir Marboxil · Drug: Placebo to Oseltamivir

  • Active comparator
    Adults: Oseltamivir

    Participants aged 20 to 64 years will receive 75 mg oseltamivir twice a day on Days 1 to 5 and two or four baloxavir marboxil placebo tablets on Day 1.

    Drug: Placebo to Baloxavir Marboxil · Drug: Oseltamivir

  • Placebo comparator
    Adults: Placebo

    Participants aged 20 to 64 years will receive two or four baloxavir marboxil placebo tablets on Day 1 and one oseltamivir placebo capsule orally twice a day on Days 1 to 5.

    Drug: Placebo to Baloxavir Marboxil · Drug: Placebo to Oseltamivir

  • Experimental
    Adolescents: Baloxavir Marboxil

    Participants aged 12 to 19 years will receive two or four baloxavir marboxil 20 mg tablets on Day 1.

    Drug: Baloxavir Marboxil

  • Placebo comparator
    Adolescents: Placebo

    Participants aged 12 to 19 years will receive two or four baloxavir marboxil placebo tablets on Day 1.

    Drug: Placebo to Baloxavir Marboxil

Interventions

  • 2 to4 X 20-mg tablets taken orally

    Also known as: S-033188

  • DrugPlacebo to Baloxavir Marboxil

    2 to4 X 20-mg tablets taken orally

  • 75 mg capsules taken orally

    Also known as: Tamiflu®

  • DrugPlacebo to Oseltamivir

    Placebo capsules matching oseltamivir 75 mg capsules

06

What researchers measure

Primary outcomes

  1. Time to Alleviation of Symptoms in Participants Randomized to Baloxavir or Placebo

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of symptoms was analyzed using the Kaplan-Meier (KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time point.

    Time frame: Initiation of study treatment up to Day 14

  2. Time to Alleviation of Symptoms in Adults Randomized to Baloxavir or Oseltamivir

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of symptoms was analyzed using the Kaplan-Meier(KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time point.

    Time frame: Initiation of study treatment up to Day 14

Secondary outcomes

  1. Percentage of Participants With Positive Influenza Virus Titer at Each Time Point in Participants Randomized to Baloxavir or Placebo

    Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6 and 9.

    Time frame: Days 2, 3, 4 (optional), 5, 6 (optional), and 9

  2. Percentage of Participants With Positive Influenza Virus Titer at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir

    Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6 and 9.

    Time frame: Days 2, 3, 4 (optional), 5, 6 (optional), and 9

  3. Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Participants Randomized to Baloxavir or Placebo

    Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) among those assessed measured by reverse transcription polymerase chain reaction (RT-PCR) on Days 2, 3, 4, 5, 6 and 9.

    Time frame: Days 2, 3, 4 (optional), 5, 6 (optional), and 9

  4. Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir

    Influenza virus RNA was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) among those assessed measured by reverse transcription polymerase chain reaction (RT-PCR) on Days 2, 3, 4, 5, 6 and 9.

    Time frame: Days 2, 3, 4 (optional), 5, 6 (optional), and 9

  5. Change From Baseline in Virus Titer at Each Time Point in Participants Randomized to Baloxavir or Placebo

    Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).

    Time frame: Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9

  6. Change From Baseline in Virus Titer at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir

    Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).

    Time frame: Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9

  7. Change From Baseline in Virus RNA (RT-PCR) at Each Time Point in Participants Randomized to Baloxavir or Placebo

    Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA is measured by reverse transcription polymerase chain reaction (RT-PCR).

    Time frame: Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9

  8. Change From Baseline in Virus RNA (RT-PCR) at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir

    Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA was measured by reverse transcription polymerase chain reaction (RT-PCR).

    Time frame: Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9

  9. Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Participants Randomized to Baloxavir or Placebo

    This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.

    Time frame: Day 1 to Day 9

  10. Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Adults Randomized to Baloxavir or Oseltamivir

    This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.

    Time frame: Day 1 to Day 9

  11. Area Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Participants Randomized to Baloxavir or Placebo

    This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.

    Time frame: Day 1 to Day 9

  12. Area Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Adults Randomized to Baloxavir or Oseltamivir

    This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.

    Time frame: Day 1 to Day 9

  13. Time to Cessation of Viral Shedding Determined by Virus Titer in Participants Randomized to Baloxavir or Placebo

    Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀\[TCID₅₀/mL\]). The median and 95% confidence interval (CI) for time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.

    Time frame: Day 1 to Day 9

  14. Time to Cessation of Viral Shedding Determined by Virus Titer in Adults Randomized to Baloxavir or Oseltamivir

    Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀\[TCID₅₀/mL\]). The time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.

    Time frame: Day 1 to Day 9

  15. Time to Cessation of Viral Shedding Determined by Virus RNA in Participants Randomized to Baloxavir or Placebo

    Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR. Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.

    Time frame: Day 1 to Day 9

  16. Time to Cessation of Viral Shedding Determined by Virus RNA in Adults Randomized to Baloxavir or Oseltamivir

    Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR. Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.

    Time frame: Day 1 to Day 9

  17. Percentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Participants Randomized to Baloxavir or Placebo

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1) .

    Time frame: 12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment

  18. Percentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1) .

    Time frame: 12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment

  19. Time to Alleviation of the Four Systemic Symptoms in Participants Randomized to Baloxavir or Placebo

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours. Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.

    Time frame: Initiation of study treatment up to Day 14

  20. Time to Alleviation of the Four Systemic Symptoms in Adults Randomized to Baloxavir or Oseltamivir

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours. Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.

    Time frame: Initiation of study treatment up to Day 14

  21. Time to Alleviation of the Three Respiratory Symptoms in Participants Randomized to Baloxavir or Placebo

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time point.

    Time frame: Initiation of study treatment up to Day 14

  22. Time to Alleviation of the Three Respiratory Symptoms in Adults Randomized to Baloxavir or Oseltamivir

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time point.

    Time frame: Initiation of study treatment up to Day 14

  23. Change From Baseline in Composite Symptom Score at Each Time Point in Participants Randomized to Baloxavir or Placebo

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant, and ranges from 0 to 21.

    Time frame: Day 1 pretreatment (Baseline) and 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment.

  24. Change From Baseline in Composite Symptom Score at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant, and ranges from 0 to 21.

    Time frame: Day 1 pretreatment (Baseline) and 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment.

  25. Time to Resolution of Fever in Participants Randomized to Baloxavir or Placebo

    Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours. Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.

    Time frame: Initiation of study treatment up to Day 14

  26. Time to Resolution of Fever in Adults Randomized to Baloxavir or Oseltamivir

    Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours. Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.

    Time frame: Initiation of study treatment up to Day 14

  27. Percentage of Participants Reporting Normal Temperature at Each Time Point in Participants Randomized to Baloxavir or Placebo

    Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment.

    Time frame: 12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment

  28. Percentage of Participants Reporting Normal Temperature at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir

    Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment.

    Time frame: 12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment

  29. Body Temperature at Each Time Point in Participants Randomized to Baloxavir or Placebo

    Participant's self-measured axillary temperature using an electronic thermometer.

    Time frame: 12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment

  30. Body Temperature at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir

    Participant's self-measured axillary temperature using an electronic thermometer.

    Time frame: 12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment

  31. Time to Alleviation of Individual Symptoms in Participants Randomized to Baloxavir or Placebo

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.

    Time frame: Initiation of study treatment up to Day 14

  32. Time to Alleviation of Individual Symptoms in Adults Randomized to Baloxavir or Oseltamivir

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.

    Time frame: Initiation of study treatment up to Day 14

  33. Time to Return to Preinfluenza Health Status in Participants Randomized to Baloxavir or Placebo

    Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health \[for someone your age and your health condition\]), and their health status every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score. Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.

    Time frame: Initiation of study treatment up to Day 14

  34. Time to Return to Preinfluenza Health Status in Adults Randomized to Baloxavir or Oseltamivir

    Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health \[for someone your age and your health condition\]), and their health status every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score. Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.

    Time frame: Initiation of study treatment up to Day 14

  35. Percentage of Participants With Influenza-related Complications in Participants Randomized to Baloxavir or Placebo

    The percentage of participants who experienced each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically confirmed pneumonia) as an adverse event after the initiation of the study treatment.

    Time frame: Initiation of study treatment up to Day 14

  36. Percentage of Participants With Influenza-related Complications in Adults Randomized to Baloxavir or Oseltamivir

    The percentage of participants who experienced each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically confirmed pneumonia) as an adverse event after the initiation of the study treatment.

    Time frame: Initiation of study treatment up to Day 14

  37. Percentage of Participants With Adverse Events (AEs)

    Time frame: From first dose of study drug to Day 22

07

Results

Posted Dec 14, 2018

Participant flow

This study was conducted at 297 sites, consisting of 141 sites in Japan, 149 sites in the United States, and 7 sites in Canada. Participants were enrolled from December 2016 to April 2017.

Participant flow — Overall Study
MilestoneBaloxavirPlaceboOseltamivir
Started612310514
Received study drug610309513
Intention to treat infected population456231377
Completed578290498
Not completed342016
Withdrew: Adverse event224
Withdrew: Failure to meet eligibility criteria100
Withdrew: Lack of efficacy020
Withdrew: Withdrawal by subject17911
Withdrew: Lost to follow-up1250
Withdrew: Miscellaneous221

Outcome measures

PrimaryTime to Alleviation of Symptoms in Participants Randomized to Baloxavir or Placebo

Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of symptoms was analyzed using the Kaplan-Meier (KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time point.

Time frame:
Initiation of study treatment up to Day 14
Reported as:
Median · hours
Time to Alleviation of Symptoms in Participants Randomized to Baloxavir or Placebo
hoursBaloxavirPlacebo
Time to Alleviation of Symptoms in Participants Randomized to Baloxavir or Placebo53.7 (49.5 to 58.5)80.2 (72.6 to 87.1)
Statistical analysis
  • Baloxavir vs Placebo · Generalized Wilcoxon test · p = <0.0001 (Adjusted p-value, two-sided significance level of 0.05) · Difference: -26.5 · 95% CI -35.8 to -17.8Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Log Rank · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Log rank test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
PrimaryTime to Alleviation of Symptoms in Adults Randomized to Baloxavir or Oseltamivir

Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of symptoms was analyzed using the Kaplan-Meier(KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time point.

Time frame:
Initiation of study treatment up to Day 14
Reported as:
Median · hours
Time to Alleviation of Symptoms in Adults Randomized to Baloxavir or Oseltamivir
hoursBaloxavirOseltamivir
Time to Alleviation of Symptoms in Adults Randomized to Baloxavir or Oseltamivir53.5 (48.0 to 58.5)53.8 (50.2 to 56.4)
Statistical analysis
  • Baloxavir vs Oseltamivir · Generalized Wilcoxon test · p = 0.7560 (Adjusted p-value, two-sided significance level of 0.05) · Difference: -0.3 · 95% CI -6.6 to 6.6Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Log Rank · p = 0.3761 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Log rank test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryPercentage of Participants With Positive Influenza Virus Titer at Each Time Point in Participants Randomized to Baloxavir or Placebo

Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6 and 9.

Time frame:
Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Influenza Virus Titer at Each Time Point in Participants Randomized to Baloxavir or Placebo
percentage of participantsBaloxavirPlacebo
Day 247.6 (42.7 to 52.5)96.0 (92.3 to 98.3)
Day 321.7 (17.8 to 26.0)70.5 (63.5 to 76.8)
Day 416.7 (10.3 to 24.8)56.1 (42.4 to 69.3)
Day 513.5 (10.4 to 17.3)29.7 (23.3 to 36.7)
Day 68.2 (3.6 to 15.6)12.5 (4.7 to 25.2)
Day 92.9 (1.5 to 5.1)4.6 (2.1 to 8.5)
Statistical analysis
  • Baloxavir vs Placebo · Mantel Haenszel · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.4767 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.3353 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryPercentage of Participants With Positive Influenza Virus Titer at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir

Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6 and 9.

Time frame:
Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Influenza Virus Titer at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir
percentage of participantsBaloxavirOseltamivir
Day 247.4 (41.9 to 52.8)91.1 (87.6 to 93.9)
Day 320.0 (15.8 to 24.7)57.3 (51.9 to 62.6)
Day 416.1 (9.1 to 25.5)27.6 (19.3 to 37.2)
Day 512.9 (9.5 to 17.0)20.8 (16.6 to 25.6)
Day 65.6 (1.6 to 13.8)9.0 (3.7 to 17.6)
Day 93.0 (1.4 to 5.4)3.2 (1.6 to 5.7)
Statistical analysis
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.0852 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.0063 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.6187 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.8637 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)
SecondaryPercentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Participants Randomized to Baloxavir or Placebo

Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) among those assessed measured by reverse transcription polymerase chain reaction (RT-PCR) on Days 2, 3, 4, 5, 6 and 9.

Time frame:
Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Participants Randomized to Baloxavir or Placebo
percentage of participantsBaloxavirPlacebo
Day 297.3 (95.3 to 98.6)97.7 (94.8 to 99.3)
Day 395.6 (93.3 to 97.4)97.2 (94.0 to 99.0)
Day 493.4 (87.5 to 97.1)91.0 (81.5 to 96.6)
Day 587.4 (83.9 to 90.4)93.9 (89.8 to 96.7)
Day 674.8 (65.2 to 82.8)77.2 (64.2 to 87.3)
Day 961.5 (56.7 to 66.1)72.4 (65.9 to 78.2)
Statistical analysis
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.6145 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.2505 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.4190 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.0095 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.7393 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.0049 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryPercentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir

Influenza virus RNA was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) among those assessed measured by reverse transcription polymerase chain reaction (RT-PCR) on Days 2, 3, 4, 5, 6 and 9.

Time frame:
Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir
percentage of participantsBaloxavirOseltamivir
Day 297.3 (95.0 to 98.7)98.6 (96.8 to 99.6)
Day 395.3 (92.5 to 97.2)97.5 (95.3 to 98.9)
Day 493.6 (86.6 to 97.6)93.0 (86.8 to 96.9)
Day 586.6 (82.6 to 89.9)92.1 (88.7 to 94.7)
Day 669.3 (57.6 to 79.5)80.7 (70.6 to 88.6)
Day 960.2 (54.9 to 65.3)64.7 (59.5 to 69.7)
Statistical analysis
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.2266 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.1379 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.5479 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.0241 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.0898 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.2548 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryChange From Baseline in Virus Titer at Each Time Point in Participants Randomized to Baloxavir or Placebo

Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).

Time frame:
Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Reported as:
Mean · log₁₀[TCID₅₀/mL]
Change From Baseline in Virus Titer at Each Time Point in Participants Randomized to Baloxavir or Placebo
log₁₀[TCID₅₀/mL]BaloxavirPlacebo
Day 2-4.45 ± 2.03-1.19 ± 2.43
Day 3-4.82 ± 1.99-2.88 ± 2.88
Day 4-4.50 ± 2.02-3.31 ± 2.34
Day 5-4.95 ± 1.93-4.47 ± 2.21
Day 6-4.58 ± 1.99-4.68 ± 2.12
Day 9-5.06 ± 1.87-4.87 ± 1.85
Statistical analysis
  • Baloxavir vs Placebo · van Elteren test · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · van Elteren test · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · van Elteren test · p = 0.0008 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · van Elteren test · p = 0.0132 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · van Elteren test · p = 0.9307 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · van Elteren test · p = 0.1677 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryChange From Baseline in Virus Titer at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir

Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).

Time frame:
Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Reported as:
Mean · log₁₀[TCID₅₀/mL]
Change From Baseline in Virus Titer at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir
log₁₀[TCID₅₀/mL]BaloxavirOseltamivir
Day 2-4.39 ± 2.07-2.53 ± 2.03
Day 3-4.79 ± 2.03-4.20 ± 2.02
Day 4-4.46 ± 2.03-4.63 ± 1.89
Day 5-4.95 ± 1.94-4.98 ± 1.81
Day 6-4.56 ± 1.99-4.85 ± 1.95
Day 9-5.03 ± 1.89-5.22 ± 1.70
Statistical analysis
  • Baloxavir vs Oseltamivir · van Elteren test · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · van Elteren test · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · van Elteren test · p = 0.8010 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · van Elteren test · p = 0.9451 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · van Elteren test · p = 0.2256 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · van Elteren test · p = 0.3332 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryChange From Baseline in Virus RNA (RT-PCR) at Each Time Point in Participants Randomized to Baloxavir or Placebo

Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA is measured by reverse transcription polymerase chain reaction (RT-PCR).

Time frame:
Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Reported as:
Mean · log₁₀ virus particles/mL
Change From Baseline in Virus RNA (RT-PCR) at Each Time Point in Participants Randomized to Baloxavir or Placebo
log₁₀ virus particles/mLBaloxavirPlacebo
Day 2-1.63 ± 1.03-0.56 ± 1.37
Day 3-2.80 ± 1.20-1.61 ± 1.76
Day 4-3.07 ± 1.59-1.95 ± 1.76
Day 5-3.75 ± 1.47-3.04 ± 1.62
Day 6-3.83 ± 1.64-3.03 ± 1.85
Day 9-4.43 ± 1.42-4.06 ± 1.47
Statistical analysis
  • Baloxavir vs Placebo · van Elteren test · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · van Elteren test · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · van Elteren test · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · van Elteren test · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · van Elteren test · p = 0.0010 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · van Elteren test · p = 0.0002 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryChange From Baseline in Virus RNA (RT-PCR) at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir

Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA was measured by reverse transcription polymerase chain reaction (RT-PCR).

Time frame:
Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Reported as:
Mean · log₁₀ virus particles/mL
Change From Baseline in Virus RNA (RT-PCR) at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir
log₁₀ virus particles/mLBaloxavirOseltamivir
Day 2-1.61 ± 1.06-1.10 ± 1.10
Day 3-2.79 ± 1.21-2.44 ± 1.24
Day 4-2.94 ± 1.62-2.97 ± 1.29
Day 5-3.76 ± 1.44-3.62 ± 1.34
Day 6-3.81 ± 1.52-3.88 ± 1.35
Day 9-4.43 ± 1.43-4.52 ± 1.22
Statistical analysis
  • Baloxavir vs Oseltamivir · van Elteren test · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · van Elteren test · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · van Elteren test · p = 0.4148 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · van Elteren test · p = 0.0338 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · van Elteren test · p = 0.9619 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · van Elteren test · p = 0.8491 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryArea Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Participants Randomized to Baloxavir or Placebo

This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.

Time frame:
Day 1 to Day 9
Reported as:
Mean · log₁₀[TCID₅₀/mL]*hours
Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Participants Randomized to Baloxavir or Placebo
log₁₀[TCID₅₀/mL]*hoursBaloxavirPlacebo
Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Participants Randomized to Baloxavir or Placebo-836.2 ± 348.9-641.8 ± 377.6
Statistical analysis
  • Baloxavir vs Placebo · van Elteren test · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryArea Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Adults Randomized to Baloxavir or Oseltamivir

This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.

Time frame:
Day 1 to Day 9
Reported as:
Mean · log₁₀[TCID₅₀/mL]*hours
Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Adults Randomized to Baloxavir or Oseltamivir
log₁₀[TCID₅₀/mL]*hoursBaloxavirOseltamivir
Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Adults Randomized to Baloxavir or Oseltamivir-829.6 ± 350.3-790.2 ± 328.4
Statistical analysis
  • Baloxavir vs Oseltamivir · van Elteren test · p = 0.0313 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryArea Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Participants Randomized to Baloxavir or Placebo

This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.

Time frame:
Day 1 to Day 9
Reported as:
Mean · log₁₀ virus particles/mL*hours
Area Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Participants Randomized to Baloxavir or Placebo
log₁₀ virus particles/mL*hoursBaloxavirPlacebo
Area Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Participants Randomized to Baloxavir or Placebo-582.0 ± 230.9-456.8 ± 269.6
Statistical analysis
  • Baloxavir vs Placebo · van Elteren test · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryArea Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Adults Randomized to Baloxavir or Oseltamivir

This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.

Time frame:
Day 1 to Day 9
Reported as:
Mean · log₁₀ virus particles/mL*hours
Area Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Adults Randomized to Baloxavir or Oseltamivir
log₁₀ virus particles/mL*hoursBaloxavirOseltamivir
Area Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Adults Randomized to Baloxavir or Oseltamivir-581.0 ± 231.2-569.7 ± 228.8
Statistical analysis
  • Baloxavir vs Oseltamivir · van Elteren test · p = 0.2424 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryTime to Cessation of Viral Shedding Determined by Virus Titer in Participants Randomized to Baloxavir or Placebo

Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀\[TCID₅₀/mL\]). The median and 95% confidence interval (CI) for time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.

Time frame:
Day 1 to Day 9
Reported as:
Median · hours
Time to Cessation of Viral Shedding Determined by Virus Titer in Participants Randomized to Baloxavir or Placebo
hoursBaloxavirPlacebo
Time to Cessation of Viral Shedding Determined by Virus Titer in Participants Randomized to Baloxavir or Placebo24.0 (24.0 to 48.0)96.0 (NA to NA)
Statistical analysis
  • Baloxavir vs Placebo · Generalized Wilcoxon test · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: -72.0 · 95% CI -72.0 to -48.0Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryTime to Cessation of Viral Shedding Determined by Virus Titer in Adults Randomized to Baloxavir or Oseltamivir

Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀\[TCID₅₀/mL\]). The time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.

Time frame:
Day 1 to Day 9
Reported as:
Median · hours
Time to Cessation of Viral Shedding Determined by Virus Titer in Adults Randomized to Baloxavir or Oseltamivir
hoursBaloxavirOseltamivir
Time to Cessation of Viral Shedding Determined by Virus Titer in Adults Randomized to Baloxavir or Oseltamivir24.0 (24.0 to 48.0)72.0 (72.0 to 96.0)
Statistical analysis
  • Baloxavir vs Oseltamivir · Generalized Wilcoxon test · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: -48.0 · 95% CI -72.0 to -24.0Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryTime to Cessation of Viral Shedding Determined by Virus RNA in Participants Randomized to Baloxavir or Placebo

Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR. Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.

Time frame:
Day 1 to Day 9
Reported as:
Median · hours
Time to Cessation of Viral Shedding Determined by Virus RNA in Participants Randomized to Baloxavir or Placebo
hoursBaloxavirPlacebo
Time to Cessation of Viral Shedding Determined by Virus RNA in Participants Randomized to Baloxavir or Placebo216.0 (216.0 to 240.0)240.0 (240.0 to 336.0)
Statistical analysis
  • Baloxavir vs Placebo · Generalized Wilcoxon test · p = 0.0020 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: -24.0 · 95% CI -120.0 to 0.0Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryTime to Cessation of Viral Shedding Determined by Virus RNA in Adults Randomized to Baloxavir or Oseltamivir

Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR. Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.

Time frame:
Day 1 to Day 9
Reported as:
Median · hours
Time to Cessation of Viral Shedding Determined by Virus RNA in Adults Randomized to Baloxavir or Oseltamivir
hoursBaloxavirOseltamivir
Time to Cessation of Viral Shedding Determined by Virus RNA in Adults Randomized to Baloxavir or Oseltamivir216.0 (192.0 to 240.0)240.0 (216.0 to 240.0)
Statistical analysis
  • Baloxavir vs Oseltamivir · Generalized Wilcoxon test · p = 0.0102 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: -24.0 · 95% CI -48.0 to 24.0Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryPercentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Participants Randomized to Baloxavir or Placebo

Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1) .

Time frame:
12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment
Reported as:
Number · percentage of participants
Percentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Participants Randomized to Baloxavir or Placebo
percentage of participantsBaloxavirPlacebo
12 hours9.7 (6.9 to 13.1)8.1 (4.7 to 12.9)
24 hours23.1 (19.3 to 27.3)12.8 (8.7 to 18.0)
36 hours42.4 (37.2 to 47.7)23.1 (17.4 to 29.6)
48 hours50.7 (45.9 to 55.4)26.4 (20.7 to 32.7)
72 hours68.9 (64.3 to 73.3)49.5 (42.7 to 56.4)
96 hours78.6 (74.4 to 82.3)69.9 (63.3 to 75.9)
120 hours85.5 (81.8 to 88.8)81.6 (75.7 to 86.6)
144 hours89.1 (85.7 to 92.0)85.4 (79.7 to 90.0)
168 hours91.6 (88.4 to 94.1)88.3 (83.0 to 92.5)
192 hours90.9 (87.7 to 93.5)91.4 (86.5 to 94.9)
216 hours91.1 (86.5 to 94.5)91.9 (85.2 to 96.2)
Statistical analysis
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.5973 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.0010 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.0115 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.1298 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.1170 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.0757 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.9453 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.8657 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryPercentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir

Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1) .

Time frame:
12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment
Reported as:
Number · percentage of participants
Percentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir
percentage of participantsBaloxavirOseltamivir
12 hours8.7 (5.8 to 12.4)4.9 (2.7 to 7.9)
24 hours21.3 (17.2 to 25.9)22.7 (18.5 to 27.4)
36 hours41.1 (35.5 to 46.9)38.7 (33.1 to 44.5)
48 hours51.0 (45.7 to 56.2)54.4 (49.1 to 59.7)
72 hours70.7 (65.6 to 75.4)73.0 (68.1 to 77.5)
96 hours79.8 (75.2 to 83.9)80.5 (76.0 to 84.5)
120 hours86.1 (82.0 to 89.6)87.0 (82.9 to 90.3)
144 hours89.2 (85.4 to 92.3)91.3 (87.8 to 94.1)
168 hours91.4 (87.8 to 94.1)94.3 (91.3 to 96.5)
192 hours90.8 (87.2 to 93.7)95.5 (92.6 to 97.4)
216 hours90.9 (85.8 to 94.6)96.3 (92.5 to 98.5)
Statistical analysis
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.0458 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.7565 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.3297 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.4442 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.6029 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.9881 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.9257 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.5317 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.2144 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.0413 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.0409 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryTime to Alleviation of the Four Systemic Symptoms in Participants Randomized to Baloxavir or Placebo

Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours. Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.

Time frame:
Initiation of study treatment up to Day 14
Reported as:
Median · hours
Time to Alleviation of the Four Systemic Symptoms in Participants Randomized to Baloxavir or Placebo
hoursBaloxavirPlacebo
Time to Alleviation of the Four Systemic Symptoms in Participants Randomized to Baloxavir or Placebo33.8 (31.0 to 38.3)53.5 (45.9 to 57.3)
Statistical analysis
  • Baloxavir vs Placebo · Generalized Wilcoxon test · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: -19.8Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryTime to Alleviation of the Four Systemic Symptoms in Adults Randomized to Baloxavir or Oseltamivir

Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours. Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.

Time frame:
Initiation of study treatment up to Day 14
Reported as:
Median · hours
Time to Alleviation of the Four Systemic Symptoms in Adults Randomized to Baloxavir or Oseltamivir
hoursBaloxavirOseltamivir
Time to Alleviation of the Four Systemic Symptoms in Adults Randomized to Baloxavir or Oseltamivir36.7 (32.0 to 40.1)37.4 (31.5 to 42.4)
Statistical analysis
  • Baloxavir vs Oseltamivir · Generalized Wilcoxon test · p = 0.4194 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: -0.7Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryTime to Alleviation of the Three Respiratory Symptoms in Participants Randomized to Baloxavir or Placebo

Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time point.

Time frame:
Initiation of study treatment up to Day 14
Reported as:
Median · hours
Time to Alleviation of the Three Respiratory Symptoms in Participants Randomized to Baloxavir or Placebo
hoursBaloxavirPlacebo
Time to Alleviation of the Three Respiratory Symptoms in Participants Randomized to Baloxavir or Placebo46.0 (43.4 to 50.6)69.1 (63.9 to 78.1)
Statistical analysis
  • Baloxavir vs Placebo · Generalized Wilcoxon test · p = <0.0001 · Difference: -23.1Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryTime to Alleviation of the Three Respiratory Symptoms in Adults Randomized to Baloxavir or Oseltamivir

Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time point.

Time frame:
Initiation of study treatment up to Day 14
Reported as:
Median · hours
Time to Alleviation of the Three Respiratory Symptoms in Adults Randomized to Baloxavir or Oseltamivir
hoursBaloxavirOseltamivir
Time to Alleviation of the Three Respiratory Symptoms in Adults Randomized to Baloxavir or Oseltamivir46.0 (42.7 to 52.0)44.6 (40.6 to 49.5)
Statistical analysis
  • Baloxavir vs Oseltamivir · Generalized Wilcoxon test · p = 0.4856 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: 1.3Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryChange From Baseline in Composite Symptom Score at Each Time Point in Participants Randomized to Baloxavir or Placebo

Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant, and ranges from 0 to 21.

Time frame:
Day 1 pretreatment (Baseline) and 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment.
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Composite Symptom Score at Each Time Point in Participants Randomized to Baloxavir or Placebo
scores on a scaleBaloxavirPlacebo
12 hours-2.4 ± 0.2-2.5 ± 0.3
24 hours-4.7 ± 0.2-3.6 ± 0.3
36 hours-6.7 ± 0.2-4.9 ± 0.3
48 hours-7.8 ± 0.2-6.0 ± 0.3
72 hours-9.4 ± 0.2-8.0 ± 0.2
96 hours-10.5 ± 0.2-9.5 ± 0.2
120 hours-10.9 ± 0.2-10.6 ± 0.2
144 hours-11.6 ± 0.1-11.2 ± 0.2
168 hours-11.9 ± 0.1-11.8 ± 0.2
192 hours-12.0 ± 0.1-12.0 ± 0.2
216 hours-12.4 ± 0.2-12.4 ± 0.3
Statistical analysis
  • Baloxavir vs Placebo · ANCOVA · p = 0.7173 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.1 · 95% CI -0.5 to 0.7Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Placebo · ANCOVA · p = 0.0009 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -1.1 · 95% CI -1.7 to -0.4Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Placebo · ANCOVA · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -1.8 · 95% CI -2.4 to -1.1Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Placebo · ANCOVA · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -1.8 · 95% CI -2.4 to -1.2Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Placebo · ANCOVA · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -1.4 · 95% CI -2.0 to -0.9Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Placebo · ANCOVA · p = 0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -1.0 · 95% CI -1.5 to -0.5Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Placebo · ANCOVA · p = 0.1979 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.3 · 95% CI -0.8 to 0.2Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Placebo · ANCOVA · p = 0.1079 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.4 · 95% CI -0.8 to 0.1Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Placebo · ANCOVA · p = 0.5805 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.1 · 95% CI -0.6 to 0.3Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Placebo · ANCOVA · p = 0.8057 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.1 · 95% CI -0.4 to 0.5Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Placebo · ANCOVA · p = 0.9525 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.0 · 95% CI -0.6 to 0.6Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
SecondaryChange From Baseline in Composite Symptom Score at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir

Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant, and ranges from 0 to 21.

Time frame:
Day 1 pretreatment (Baseline) and 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment.
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Composite Symptom Score at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir
scores on a scaleBaloxavirOseltamivir
12 hours-2.2 ± 0.2-2.4 ± 0.2
24 hours-4.5 ± 0.2-4.7 ± 0.2
36 hours-6.5 ± 0.2-6.3 ± 0.2
48 hours-7.6 ± 0.2-7.8 ± 0.2
72 hours-9.6 ± 0.2-9.7 ± 0.2
96 hours-10.5 ± 0.2-10.6 ± 0.2
120 hours-11.0 ± 0.2-11.3 ± 0.2
144 hours-11.8 ± 0.2-11.8 ± 0.2
168 hours-11.9 ± 0.2-12.1 ± 0.2
192 hours-12.0 ± 0.1-12.4 ± 0.2
216 hours-12.4 ± 0.2-12.5 ± 0.2
Statistical analysis
  • Baloxavir vs Oseltamivir · ANCOVA · p = 0.4091 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.2 · 95% CI -0.3 to 0.8Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Oseltamivir · ANCOVA · p = 0.3073 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.3 · 95% CI -0.3 to 0.8Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Oseltamivir · ANCOVA · p = 0.3465 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.3 · 95% CI -0.8 to 0.3Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Oseltamivir · ANCOVA · p = 0.4285 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.2 · 95% CI -0.3 to 0.7Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Oseltamivir · ANCOVA · p = 0.6703 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.1 · 95% CI -0.4 to 0.6Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Oseltamivir · ANCOVA · p = 0.7187 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.1 · 95% CI -0.3 to 0.5Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Oseltamivir · ANCOVA · p = 0.1350 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.3 · 95% CI -0.1 to 0.7Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Oseltamivir · ANCOVA · p = 0.7046 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.1 · 95% CI -0.3 to 0.5Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Oseltamivir · ANCOVA · p = 0.2765 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.2 · 95% CI -0.2 to 0.6Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Oseltamivir · ANCOVA · p = 0.0274 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.4 · 95% CI 0.0 to 0.8Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
  • Baloxavir vs Oseltamivir · ANCOVA · p = 0.6001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.1 · 95% CI -0.3 to 0.6Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.
SecondaryTime to Resolution of Fever in Participants Randomized to Baloxavir or Placebo

Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours. Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.

Time frame:
Initiation of study treatment up to Day 14
Reported as:
Median · hours
Time to Resolution of Fever in Participants Randomized to Baloxavir or Placebo
hoursBaloxavirPlacebo
Time to Resolution of Fever in Participants Randomized to Baloxavir or Placebo24.5 (22.6 to 26.6)42.0 (37.4 to 44.6)
Statistical analysis
  • Baloxavir vs Placebo · Generalized Wilcoxon test · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: -17.5 · 95% CI -21.1 to -11.9Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryTime to Resolution of Fever in Adults Randomized to Baloxavir or Oseltamivir

Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours. Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.

Time frame:
Initiation of study treatment up to Day 14
Reported as:
Median · hours
Time to Resolution of Fever in Adults Randomized to Baloxavir or Oseltamivir
hoursBaloxavirOseltamivir
Time to Resolution of Fever in Adults Randomized to Baloxavir or Oseltamivir24.4 (22.2 to 26.5)24.0 (22.1 to 25.9)
Statistical analysis
  • Baloxavir vs Oseltamivir · Generalized Wilcoxon test · p = 0.9225 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryPercentage of Participants Reporting Normal Temperature at Each Time Point in Participants Randomized to Baloxavir or Placebo

Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment.

Time frame:
12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Normal Temperature at Each Time Point in Participants Randomized to Baloxavir or Placebo
percentage of participantsBaloxavirPlacebo
12 hours26.5 (22.3 to 30.9)25.3 (19.7 to 31.7)
24 hours64.3 (59.6 to 68.7)48.4 (41.8 to 55.2)
36 hours80.8 (76.8 to 84.5)58.3 (51.4 to 64.9)
48 hours89.3 (86.0 to 92.0)67.3 (60.6 to 73.4)
72 hours93.7 (90.9 to 95.8)83.8 (77.8 to 88.6)
96 hours92.8 (89.8 to 95.1)93.9 (89.6 to 96.8)
120 hours92.9 (89.8 to 95.2)92.8 (88.2 to 96.0)
144 hours93.4 (90.4 to 95.7)93.6 (89.1 to 96.6)
168 hours93.3 (90.3 to 95.6)93.6 (89.1 to 96.6)
192 hours94.1 (91.2 to 96.3)93.7 (89.3 to 96.7)
216 hours92.5 (89.3 to 94.9)92.7 (88.0 to 95.9)
Statistical analysis
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.7866 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.7044 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.8512 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.8783 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.8291 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.8644 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Mantel Haenszel · p = 0.9312 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryPercentage of Participants Reporting Normal Temperature at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir

Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment.

Time frame:
12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Normal Temperature at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir
percentage of participantsBaloxavirOseltamivir
12 hours25.0 (20.6 to 29.8)28.3 (23.7 to 33.3)
24 hours64.3 (59.1 to 69.2)66.8 (61.7 to 71.6)
36 hours81.9 (77.5 to 85.8)79.1 (74.5 to 83.2)
48 hours90.1 (86.5 to 93.0)89.9 (86.3 to 92.8)
72 hours93.8 (90.7 to 96.1)89.5 (85.8 to 92.6)
96 hours93.9 (90.8 to 96.2)94.9 (92.0 to 97.0)
120 hours93.8 (90.6 to 96.2)95.8 (93.1 to 97.7)
144 hours92.8 (89.4 to 95.4)94.5 (91.5 to 96.7)
168 hours93.6 (90.3 to 96.1)95.9 (93.0 to 97.8)
192 hours94.6 (91.4 to 96.8)95.8 (92.9 to 97.7)
216 hours92.8 (89.3 to 95.4)94.5 (91.3 to 96.8)
Statistical analysis
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.2953 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.5414 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.2079 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.7771 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world)
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.0215 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.8033 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world)
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.4157 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.5908 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world)
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.2975 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.8644 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Mantel Haenszel · p = 0.5573 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.m)Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryBody Temperature at Each Time Point in Participants Randomized to Baloxavir or Placebo

Participant's self-measured axillary temperature using an electronic thermometer.

Time frame:
12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment
Reported as:
Least squares mean · °C
Body Temperature at Each Time Point in Participants Randomized to Baloxavir or Placebo
°CBaloxavirPlacebo
12 hours37.40 ± 0.0537.49 ± 0.07
24 hours36.73 ± 0.0437.07 ± 0.05
36 hours36.49 ± 0.0436.90 ± 0.05
48 hours36.32 ± 0.0336.69 ± 0.05
72 hours36.26 ± 0.0336.48 ± 0.04
96 hours36.27 ± 0.0336.31 ± 0.04
120 hours36.28 ± 0.0336.25 ± 0.04
Statistical analysis
  • Baloxavir vs Placebo · ANCOVA · p = 0.2557 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.09 · 95% CI -0.24 to 0.06ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.
  • Baloxavir vs Placebo · ANCOVA · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.34 · 95% CI -0.46 to -0.22ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.
  • Baloxavir vs Placebo · ANCOVA · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.41 · 95% CI -0.52 to -0.29ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.
  • Baloxavir vs Placebo · ANCOVA · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.37 · 95% CI -0.48 to -0.27ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.
  • Baloxavir vs Placebo · ANCOVA · p = <0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.22 · 95% CI -0.31 to -0.13ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.
  • Baloxavir vs Placebo · ANCOVA · p = 0.4484 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean dfference: -0.04 · 95% CI -0.13 to 0.06ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.
  • Baloxavir vs Placebo · ANCOVA · p = 0.5963 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.02 · 95% CI -0.07 to 0.11ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.
SecondaryBody Temperature at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir

Participant's self-measured axillary temperature using an electronic thermometer.

Time frame:
12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment
Reported as:
Least squares mean · °C
Body Temperature at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir
°CBaloxavirOseltamivir
12 hours37.47 ± 0.0537.35 ± 0.05
24 hours36.78 ± 0.0436.73 ± 0.04
36 hours36.55 ± 0.0436.54 ± 0.04
48 hours36.34 ± 0.0336.36 ± 0.03
72 hours36.30 ± 0.0336.31 ± 0.03
96 hours36.26 ± 0.0336.23 ± 0.03
120 hours36.27 ± 0.0336.21 ± 0.03
Statistical analysis
  • Baloxavir vs Oseltamivir · ANCOVA · p = 0.0937 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.11 · 95% CI -0.02 to 0.24ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.
  • Baloxavir vs Oseltamivir · ANCOVA · p = 0.3343 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.05 · 95% CI -0.05 to 0.16ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.
  • Baloxavir vs Oseltamivir · ANCOVA · p = 0.9258 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.00 · 95% CI -0.09 to 0.10ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.
  • Baloxavir vs Oseltamivir · ANCOVA · p = 0.6574 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.02 · 95% CI -0.10 to 0.06ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.
  • Baloxavir vs Oseltamivir · ANCOVA · p = 0.8520 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.01 · 95% CI -0.09 to 0.07ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.
  • Baloxavir vs Oseltamivir · ANCOVA · p = 0.4532 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.03 · 95% CI -0.05 to 0.11ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.
  • Baloxavir vs Oseltamivir · ANCOVA · p = 0.1570 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.05 · 95% CI -0.02 to 0.13ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.
SecondaryTime to Alleviation of Individual Symptoms in Participants Randomized to Baloxavir or Placebo

Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.

Time frame:
Initiation of study treatment up to Day 14
Reported as:
Median · hours
Time to Alleviation of Individual Symptoms in Participants Randomized to Baloxavir or Placebo
hoursBaloxavirPlacebo
Cough38.3 (30.3 to 43.5)61.4 (44.8 to 69.5)
Sore Throat31.5 (27.3 to 39.2)40.5 (31.8 to 48.3)
Headache26.1 (22.9 to 29.8)37.9 (25.8 to 42.2)
Nasal Congestion31.8 (29.9 to 38.7)52.5 (41.5 to 62.7)
Feverishness or chills20.9 (20.0 to 21.9)25.8 (21.7 to 31.5)
Muscle or joint pain23.2 (21.4 to 26.3)31.3 (25.5 to 39.2)
Fatigue25.3 (22.0 to 29.2)40.5 (31.2 to 46.8)
Statistical analysis
  • Baloxavir vs Placebo · Generalized Wilcoxon test · p = 0.0001 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: -23.1Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Generalized Wilcoxon test · p = 0.0298 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: -9.0Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Generalized Wilcoxon test · p = 0.0297 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: -11.8Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Generalized Wilcoxon test · p = 0.0027 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: -20.7Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Generalized Wilcoxon test · p = 0.0003 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: -4.9Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world)
  • Baloxavir vs Placebo · Generalized Wilcoxon test · p = 0.0094 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: -8.1Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Placebo · Generalized Wilcoxon test · p = 0.0007 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: -15.3Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryTime to Alleviation of Individual Symptoms in Adults Randomized to Baloxavir or Oseltamivir

Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.

Time frame:
Initiation of study treatment up to Day 14
Reported as:
Median · hours
Time to Alleviation of Individual Symptoms in Adults Randomized to Baloxavir or Oseltamivir
hoursBaloxavirOseltamivir
Cough38.2 (30.3 to 43.4)31.4 (28.6 to 36.8)
Sore Throat32.1 (27.6 to 39.8)30.4 (25.0 to 43.9)
Headache26.9 (24.5 to 30.8)25.6 (21.9 to 30.4)
Nasal Congestion33.0 (30.5 to 40.4)31.3 (26.8 to 39.8)
Feverishness or chills21.0 (20.0 to 22.0)21.2 (20.3 to 22.0)
Muscle or joint pain23.3 (21.6 to 26.7)24.0 (21.6 to 27.1)
Fatigue28.9 (23.2 to 30.5)26.6 (23.0 to 30.8)
Statistical analysis
  • Baloxavir vs Oseltamivir · Generalized Wilcoxon test · p = 0.6623 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: 6.8Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Generalized Wilcoxon test · p = 0.8184 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: 1.8Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Generalized Wilcoxon test · p = 0.9989 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: 1.3Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Generalized Wilcoxon test · p = 0.3706 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: 1.7Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Generalized Wilcoxon test · p = 0.9973 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: -0.1Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Generalized Wilcoxon test · p = 0.6760 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: -0.7Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
  • Baloxavir vs Oseltamivir · Generalized Wilcoxon test · p = 0.4241 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: 2.2Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryTime to Return to Preinfluenza Health Status in Participants Randomized to Baloxavir or Placebo

Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health \[for someone your age and your health condition\]), and their health status every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score. Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.

Time frame:
Initiation of study treatment up to Day 14
Reported as:
Median · hours
Time to Return to Preinfluenza Health Status in Participants Randomized to Baloxavir or Placebo
hoursBaloxavirPlacebo
Time to Return to Preinfluenza Health Status in Participants Randomized to Baloxavir or Placebo129.2 (122.1 to 152.3)168.8 (145.9 to 202.2)
Statistical analysis
  • Baloxavir vs Placebo · Generalized Wilcoxon test · p = 0.0563 · Difference: -39.5Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryTime to Return to Preinfluenza Health Status in Adults Randomized to Baloxavir or Oseltamivir

Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health \[for someone your age and your health condition\]), and their health status every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score. Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.

Time frame:
Initiation of study treatment up to Day 14
Reported as:
Median · hours
Time to Return to Preinfluenza Health Status in Adults Randomized to Baloxavir or Oseltamivir
hoursBaloxavirOseltamivir
Time to Return to Preinfluenza Health Status in Adults Randomized to Baloxavir or Oseltamivir127.8 (121.5 to 152.8)128.5 (122.8 to 151.0)
Statistical analysis
  • Baloxavir vs Oseltamivir · Generalized Wilcoxon test · p = 0.7176 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Difference: -0.6Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).
SecondaryPercentage of Participants With Influenza-related Complications in Participants Randomized to Baloxavir or Placebo

The percentage of participants who experienced each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically confirmed pneumonia) as an adverse event after the initiation of the study treatment.

Time frame:
Initiation of study treatment up to Day 14
Reported as:
Number · percentage of participants
Percentage of Participants With Influenza-related Complications in Participants Randomized to Baloxavir or Placebo
percentage of participantsBaloxavirPlacebo
Any complication3.5 (2.0 to 5.6)4.3 (2.1 to 7.8)
Death0 (0.0 to 0.8)0 (0.0 to 1.6)
Hospitalization0 (0.0 to 0.8)0 (0.0 to 1.6)
Sinusitis0.9 (0.2 to 2.2)0.9 (0.1 to 3.1)
Otitis media0.4 (0.1 to 1.6)0 (0.0 to 1.6)
Bronchitis2.0 (0.9 to 3.7)3.5 (1.5 to 6.7)
Pneumonia0.4 (0.1 to 1.6)0.4 (0.0 to 2.4)
Statistical analysis
  • Baloxavir vs Placebo · Fisher Exact · p = 0.6728 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)
SecondaryPercentage of Participants With Influenza-related Complications in Adults Randomized to Baloxavir or Oseltamivir

The percentage of participants who experienced each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically confirmed pneumonia) as an adverse event after the initiation of the study treatment.

Time frame:
Initiation of study treatment up to Day 14
Reported as:
Number · percentage of participants
Percentage of Participants With Influenza-related Complications in Adults Randomized to Baloxavir or Oseltamivir
percentage of participantsBaloxavirOseltamivir
Any complication4.0 (2.2 to 6.5)2.4 (1.1 to 4.5)
Death0 (0.0 to 1.0)0 (0.0 to 1.0)
Hospitalization0 (0.0 to 1.0)0.3 (0.0 to 1.5)
Sinusitis0.8 (0.2 to 2.3)0 (0.0 to 1.0)
Otitis media0.5 (0.1 to 1.9)0.3 (0.0 to 1.5)
Bronchitis2.4 (1.1 to 4.5)1.6 (0.6 to 3.4)
Pneumonia0.5 (0.1 to 1.9)0.3 (0.0 to 1.5)
Statistical analysis
  • Baloxavir vs Oseltamivir · Fisher Exact · p = 0.2217 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)
SecondaryPercentage of Participants With Adverse Events (AEs)
Time frame:
From first dose of study drug to Day 22
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs)
percentage of participantsBaloxavirPlaceboOseltamivir
Adverse events (AEs)20.724.624.8
Serious adverse events (SAEs)0.30.00.0
AEs leading to withdrawal of study drug0.30.30.4
Treatment-related adverse events (TRAEs)4.43.98.4
Treatment-related serious adverse events0.00.00.0
TRAEs leading to withdrawal of study drug0.00.30.2

Adverse events

Collected over From first dose of treatment to Day 22. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baloxavir0/610 (0%)2/610 (0.3%)47/610 (7.7%)
Placebo0/309 (0%)0/309 (0%)40/309 (12.9%)
Oseltamivir0/513 (0%)0/513 (0%)45/513 (8.8%)
Most frequent serious events
Most frequent serious events
EventBaloxavirPlaceboOseltamivir
Meningitis viralInfections and infestations1/6100/3090/513
Incarcerated inguinal herniaGastrointestinal disorders1/6100/3090/513
Most frequent other events
Most frequent other events
EventBaloxavirPlaceboOseltamivir
BronchitisInfections and infestations16/61017/30918/513
DiarrhoeaGastrointestinal disorders18/61014/30911/513
NauseaGastrointestinal disorders8/6104/30916/513
SinusitisInfections and infestations7/6108/3095/513

Baseline characteristics

Intention-to-treat infection (ITTI) population consisting of participants who received study drug with a confirmed diagnosis of influenza. Confirmation of influenza was based on the results of reverse transcription polymerase chain reaction (RT-PCR) on Day 1.

Age, Continuous
Age, Continuous(Years)BaloxavirPlaceboOseltamivirTotal
Mean33.5 ± 13.533.9 ± 13.736.0 ± 11.834.5 ± 13.0
Age, Customized
Age, Customized(Participants)BaloxavirPlaceboOseltamivirTotal
≥ 12 to ≤ 19 years80380118
≥ 20 to ≤ 29 years12161134316
≥ 30 to ≤ 39 years9247104243
≥ 40 to ≤ 49 years974877222
≥ 50 to ≤ 59 years523051133
≥ 60 to ≤ 64 years1471132
Sex: Female, Male
Sex: Female, Male(Participants)BaloxavirPlaceboOseltamivirTotal
Female224111159494
Male232120218570
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BaloxavirPlaceboOseltamivirTotal
Hispanic or Latino32112568
Not Hispanic or Latino424220352996
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BaloxavirPlaceboOseltamivirTotal
American Indian or Alaska Native0000
Asian349178305832
Black or African American1811938
Native Hawaiian or Other Pacific Islander0011
White854060185
Other4228
Time From Symptom Onset to Initiation of the Trial Regimen
Time From Symptom Onset to Initiation of the Trial Regimen(Participants)BaloxavirPlaceboOseltamivirTotal
≥ 0 to ≤ 12 hours603441135
> 12 to ≤ 24 hours17887163428
> 24 to ≤ 36 hours1396794300
> 36 to ≤ 48 hours794379201
Influenza Virus Type or Subtype on RT-PCR Assay at Enrollment
Influenza Virus Type or Subtype on RT-PCR Assay at Enrollment(Participants)BaloxavirPlaceboOseltamivirTotal
A/H1N1pdm77216
A/H3393196332921
B38203492
Mixed infection83617
Other105318
Region
Region(Participants)BaloxavirPlaceboOseltamivirTotal
Japan/Asia343175303821
Rest of the world1135674243

1 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A; Baloxavir Marboxil Investigators Group. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018 Sep 6;379(10):913-923. doi: 10.1056/NEJMoa1716197. PubMed 30184455 ↗
  • Retout S, De Buck S, Jolivet S, Duval V, Cosson V. A Pharmacokinetics-Time to Alleviation of Symptoms Model to Support Extrapolation of Baloxavir Marboxil Clinical Efficacy in Different Ethnic Groups with Influenza A or B. Clin Pharmacol Ther. 2022 Aug;112(2):372-381. doi: 10.1002/cpt.2648. Epub 2022 Jun 10. PubMed 35585696 ↗
  • Uehara T, Hayden FG, Kawaguchi K, Omoto S, Hurt AC, De Jong MD, Hirotsu N, Sugaya N, Lee N, Baba K, Shishido T, Tsuchiya K, Portsmouth S, Kida H. Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza. J Infect Dis. 2020 Jan 14;221(3):346-355. doi: 10.1093/infdis/jiz244. PubMed 31309975 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Apr 2017, 3 months.

Results were first posted in Dec 2018, 1 year 8 months after primary completion. A results delay was requested in Mar 2018.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 3 months is below that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2016
First posted
Nov 3, 2016
StartActual
Dec 8, 2016
Primary completionActual
Apr 4, 2017
CompletionActual
Apr 24, 2017
Results delay requested
Mar 1, 2018
Results first posted
Dec 14, 2018
Last update
May 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02954354
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Nov 3, 2016
Start date
Dec 8, 2016
Primary completion
Apr 4, 2017
Completion
Apr 24, 2017
Results posted
Dec 14, 2018
Last update
May 8, 2019

Study contacts

Clinical Support Help Line Shionogi Clinical Trials Administrator
study director · Shionogi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baloxavir

Start the discussion